2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
16
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Peripheral Nervous System Diseases
2
Pain
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Breast Carcinoma In Situ
2
Arthralgia
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Radiation Injuries
1
Psoriasis
1
Polyps
1
Polycystic Ovary Syndrome
1
Pelvic Inflammatory Disease
1
Ovarian Neoplasms
1
Osteoarthritis
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Interventions
Rituximab
301
Cyclophosphamide
241
Peripheral Blood Stem Cell Transplantation
115
fludarabine phosphate
111
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
81
Vincristine
79
Prednisone
79
Mycophenolic Acid
67
Doxorubicin
62
Whole-Body Irradiation
59
Cyclosporine
59
Bendamustine Hydrochloride
59
Melphalan
57
Tacrolimus
54
Busulfan
52
obinutuzumab
50
fludarabine
50
Cytarabine
49
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
33
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Fatty Acids, Omega-3
×
Clear all
NCT00455416
2008-05-21
KLYMF
Oslo University Hospital
Phase 2
Unknown
45 enrolled